Dxcover a spin-out from the University of Strathclyde is pioneering a new blood test that can detect brain tumours rapidly, allowing for early diagnosis.

Formerly known as Clinspec Dx and Co-founded by Dr Holly Butler, a postdoctoral research associate at the University of Strathclyde, the company uses revolutionary technology to provide accurate results in minutes.

With proof-of-concept and commercial / health viability tests complete, Dxcover is now undergoing diagnostic accuracy studies at Western General Hospital, Edinburgh, with an anticipated roadmap to commercial launch in 2021.

To date the company has raised £4 million, recently securing £2.4 million from existing investors to support further development of its cancer testing technology and to strengthen its scientific and operations teams.